Answers are grounded in this paper and cite their sources.
In vitro study demonstrates enhanced cytotoxicity of antibody-conjugated carboplatin chitosan nanoparticles in lung cancer cells, indicating potential for selective targeted chemotherapy.
Monoclonal antibodies (mAbs) produced against non-small cell lung cancer (NSCLC) cells have the potential to serve as targeting ligands for selective drug delivery. This study aimed to develop hybridoma-derived murine monoclonal antibodies against the A549 human lung adenocarcinoma cell line and evaluate their application in carboplatin-loaded chitosan nanoparticles (CCnp). Combining hybridoma-derived monoclonal antibodies with drug-loaded nanocarriers may enhance the selective delivery of chemotherapeutic agents to tumor cells while providing a receptor-agnostic platform for targeted therapy. Female Balb/c mice immunized with A549 (adenocarcinoma human alveolar basal epithelial) cells and fused the elicited murine splenocytes with Sp2/0 (myeloma) cells, screening the resultant hybridomas in Hypoxanthine Aminopterin Thymidine (HAT) medium. CCnp were prepared via spontaneous emulsification and conjugated with the purified mAbs (Ab-CCnp). In vitro cytotoxicity was evaluated against A549 cells using dye exclusion, sulphorhodamine B (SRB), and MTT assays; selectivity was additionally assessed via MTT on L-132 normal human lung cells. Three stable hybridoma cell lines (C4, E4, and G5) producing mAbs against A549 antigens were established, and the antibodies purified by Protein A affinity chromatography. Physicochemical characterization guided selection of the 0.25 mg/ml drug-polymer batch for antibody conjugation. Ab-CCnp showed significantly higher in vitro cytotoxicity against A549 cells than unconjugated CCnp: MTT growth inhibition increased from 48.28 ± 2.31% to 79.02 ± 2.87% at 25 µg/well. Cytotoxicity against non-target L-132 cells remained significantly lower, indicating good selectivity. Hybridoma-derived mAb-conjugated carboplatin-loaded chitosan nanoparticles demonstrated improved, in vitro cytotoxicity against A549 cells. This study provides A549-cell-line-limited proof-of-concept study, which warrants further in vivo evaluation.
No takes yet. Share an insight, caveat, or question.
Basu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: